Galmed Pharmaceuticals Ltd.
GLMD • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$4.05M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0Healthy liquidity · 6.55Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Sep 4, 2026, 12:16 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.00
Change0.00%
Market Cap$4.05M
52W Range3.29 - 13.20
Beta0.67
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio6.55
Quick Ratio6.55
Volume12.06K
Price$0.00
Change0.00%
Market Cap$4.05M
52W Range3.29 - 13.20
Beta0.67
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.00
Current Ratio6.55
Quick Ratio6.55
Volume12.06K
Avg Volume75.78K
EPS Surprise-0.29
Investment DNA
How strong this company looks for long-term investors
47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 6.55Weak profitability
Analyst view
No analyst data available now.
🧾
No insider activity
No recent insider transactions available.